Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Imugene ( (AU:IMU) ) is now available.
Imugene Limited has announced a proposed issue of securities, which includes the issuance of over 170 million new securities in various forms, such as quoted options and ordinary shares. This strategic move is expected to enhance the company’s financial flexibility and support its ongoing research and development efforts in the field of cancer immunotherapy, potentially strengthening its market position and offering new opportunities for stakeholders.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited operates in the biotechnology industry, focusing on the development of novel immunotherapies for cancer treatment. The company is known for its innovative approach in harnessing the immune system to target and eradicate cancer cells, positioning itself as a significant player in the oncology sector.
Average Trading Volume: 558,515
Technical Sentiment Signal: Sell
Current Market Cap: A$93.35M
See more insights into IMU stock on TipRanks’ Stock Analysis page.